Category ADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2022-01-11

Engineered Mesenchymal Stem Cells as a Biotherapy Platform for Targeted Photodynamic Immunotherapy of Breast Cancer

Interleukin-12 (IL12) is a pleiotropic cytokine with promising prospects for cancer immunotherapy. Though IL12 gene-based therapy could overcome the fatal hurdle of severe systemic toxicity, targeted delivery and tumor-located expression of IL12 gene remain the challenging issues yet to be solved. Photo-immunotherapy emerging as a novel and precise therapeutic strategy, which elaborately combines immune-activating agents

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2021-12-03

Robotic high-throughput biomanufacturing and functional differentiation of human pluripotent stem cells using the CompacT SelecT (CTST) platform

The CompacT SelecT (CTST) platform is a modular robotic system that integrates a full range of cell culture proceduresunder sterile conditions that mimic the manual cell culture process. These procedures include automated handling of different cell culture vessels, pipetting large and small volumes at adjustable speeds, cell counting, cell viability analysis, cell density assessment, microscopic

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT REGENERATIVE MEDICINE
PIER MARIA FORNASARI
2021-12-01

A new CRB Life Sciences Report Highlights rapid advances in the development of cell and gene therapies

Rapid advances in the development of cell and gene therapies over the past several years have heralded “an evolutionary time in medicine.” That’s the opinion of Peter Walters, Director of Advanced Therapies at CRB. That thought reflects data seen in CRB’s annual Horizon Life Sciences report that highlights the rapid expansion of the development of cell and

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT REGENERATIVE MEDICINE
PIER MARIA FORNASARI
2021-11-17

Monash University study uncovers a new understanding of how mesenchymal stromal cells benefit patients in cell therapy

The therapeutic benefit to patients receiving mesenchymal stromal cell (MSC) therapy is not because the injected cells remain viable, but because of cell death, researchers at the Monash Biomedicine Discovery Institute (BDI) have found. In recent years, significant efforts have been made to develop stem cell-based therapies for difficult-to-treat diseases. MSC therapy is regenerative cell-based

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2021-11-10

Cell therapies, Gene therapy and CAR-T cells highlighted in EFPIA Pipeline Review 2021 Update

The new EFPIA Pipeline Review reveals that infectious, inflammatory, cancer, Alzheimer’s and rare disesases areas are among the top priorities of researchers running clinical trials today to investigate new medicines and vaccines. The comprehensive report found that in 2020 alone, around 5,000 clinical trials were launched – despite the disruption caused by the COVID-19 pandemic. In fact, the volume of trials has

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2021-07-16

EMA PRAC Concludes There is No Link Between Zynteglo and AML

EMA’s safety committee, PRAC, has concluded that there is no evidence linking the viral vector in Zynteglo to a blood cancer known as acute myeloid leukemia (AML). The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that there is no evidence linking the viral vector in Zynteglo to a blood cancer known

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2021-04-15

Risdiplam improves motor function and survival in infants with SMA

PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial of Evrysdi (risdiplam), which demonstrated that infants with type 1 spinal muscular atrophy (SMA) continued to show improvements in survival and key motor milestones after two years of treatment. PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-12-16

Teaching youngsters about the magnificent world of Advanced Therapies. RESTORE Consortium experiences a new formation/information tool for disseminating CAR-T Cells Therapy in Haematologic diseases.

“Thanks to this technology and to the specific fighting capabilities of these cells, extraordinary results have been obtained: The therapy is a new hope for patients who no longer responded to other treatments. The therapy seems to have a long-lasting effect after a single application Unlike many other therapies, which benefit only a small portion

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-12-14

Data Monitoring Committee of Pluristem Phase III Critical Limb Ischemia says primary endpoint has not been reached

The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpoint PLX-PAD was well tolerated, and no safety concerns were raised Company to terminate the CLI study to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar year

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-11-17

For an Oxford University research, videogaming is positively correlated with well-being. RESTORE consortium videogame “Fragments of Life” helps to enter into CAR-T Cells breakthrough therapy in Acute Lymphoblastic Leukemia.

Conventional wisdom has it that too many cooks spoil the broth. But such judiciousness is not usually considered the basis for scientific pronouncements or international rulings on the need to limit the number of people in kitchens. But, when it comes to video games, conventional wisdom, not science, forms the basis for our thinking and

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT CAR-T